Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT with Nivolumab and BMS-986253 in Advanced Solid Tumors and Melanoma
NCT04572451Phase 1Active, not recruiting
- Start
- Nov 2021
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adakitug in solid tumor and melanoma. Primary endpoints: Rate of Dose Limiting Toxicities at 8 weeks and Response rate to SBRT/Nivolumab/BMS986253 at 1 year. Started Nov 2021; status: active, not recruiting.
02
Drugs
adakitug
03
Conditions
solid tumormelanoma
Beyond the preview
Go deeper on NCT04572451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04572451.